Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NewcelX ( (NCEL) ) just unveiled an update.
On April 30, 2026, NewcelX reported its 2025 financial results and outlined progress on NCEL-101, its stem-cell-derived islet therapy for Type 1 diabetes, developed in collaboration with Eledon Pharmaceuticals. The company highlighted a transformative 2025 that included completion of a merger, advancement of IND-enabling work, manufacturing preparations with Pluri Inc., expansion of its pipeline programs AstroRx and DOXA, and the appointment of Swiss pharma executive Julien Boisdron to its scientific advisory board.
Financially, NewcelX ended 2025 with $2.2 million in cash, an $8.3 million net loss largely driven by non-recurring non-cash finance expenses, and net operating cash use of $2.8 million. In April 2026 it strengthened its largely debt-free balance sheet with a private placement of $1.35 million and potential additional warrant proceeds, alongside access to a $25 million equity line, moves intended to accelerate NCEL-101 and broader pipeline development in 2026 and support longer-term value creation for shareholders.
More about NewcelX
NewcelX Ltd. is a clinical-stage biopharmaceutical company focused on regenerative medicine, developing stem-cell-derived therapies primarily for Type 1 diabetes. Built on a human pluripotent stem cell platform, its lead program NCEL-101 aims to provide scalable, off-the-shelf islet cell replacement, while additional candidates such as AstroRx for ALS and DOXA for narcolepsy target broader central nervous system indications.
The company’s strategy integrates cell therapy, immune protection and translational science to address major unmet medical needs in autoimmune and neurological diseases. Leveraging prior GMP manufacturing, regulatory experience and a multi-asset pipeline, NewcelX seeks to position itself as a differentiated player in functional cures for Type 1 diabetes and other serious conditions.
Average Trading Volume: 39,240
Technical Sentiment Signal: Sell
Current Market Cap: $15.59M
For detailed information about NCEL stock, go to TipRanks’ Stock Analysis page.